Thus, T cells carrying two complementary CARs against GPC3 and ASGR1 may reduce the risk of off-tumor toxicity while maintaining relatively potent antitumor activity on GPC3+ASGR1+ HCC. This evidence concerns the gene GPC3 and hepatocellular carcinoma.